Physician profile
Mao Lee
NPI 1932897444
$1,552.93
in general payments reported to CMS, 2019-2025
19 companies · $526 in 2025
The $526 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $527 · 2024: $500 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $239.95 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lilly USA, LLC | $204.85 | 2023-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $149.19 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $129.72 | 2023-2025 | |
| Gilead Sciences, INC. | $121.84 | 2024 | Vemlidy |
| Amgen INC. | $120.66 | 2024-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $112.13 | 2023-2025 | |
| Abbvie INC. | $110.95 | 2024-2025 | |
| Exact Sciences Corporation | $59.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $57.54 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $50.57 | 2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $38.90 | 2023 | |
| Dexcom, INC. | $37.39 | 2023-2025 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $24.38 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $21.12 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $19.72 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.06 | 2025 | Caplyta |
| Novo Nordisk INC | $19.05 | 2023 | Rybelsus |
| Glaxosmithkline, LLC. | $16.41 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mao Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.